Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) closed at $133.23 up 0.18% from its previous closing price of $132.99. In other words, the price has increased by $0.18 from its previous closing price. On the day, 0.57 million shares were traded. NBIX stock price reached its highest trading level at $134.44 during the session, while it also had its lowest trading level at $131.36.
Ratios:
For a deeper understanding of Neurocrine Biosciences, Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 36.66. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.12.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $136.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when BENEVICH ERIC sold 19,818 shares for $133.36 per share. The transaction valued at 2,643,020 led to the insider holds 40,778 shares of the business.
Delaet Ingrid sold 272 shares of NBIX for $37,346 on Apr 01 ’24. The Chief Regulatory Officer now owns 7,507 shares after completing the transaction at $137.30 per share. On Mar 21 ’24, another insider, Delaet Ingrid, who serves as the Chief Regulatory Officer of the company, sold 5,000 shares for $145.06 each. As a result, the insider received 725,320 and left with 7,507 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 13400272896 and an Enterprise Value of 12686182400. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 54.83, and their Forward P/E ratio for the next fiscal year is 19.10. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.03 while its Price-to-Book (P/B) ratio in mrq is 5.89. Its current Enterprise Value per Revenue stands at 6.723 whereas that against EBITDA is 30.488.
Stock Price History:
Over the past 52 weeks, NBIX has reached a high of $148.37, while it has fallen to a 52-week low of $89.04. The 50-Day Moving Average of the stock is -2.43%, while the 200-Day Moving Average is calculated to be 11.23%.
Shares Statistics:
For the past three months, NBIX has traded an average of 883.70K shares per day and 708500 over the past ten days. A total of 98.70M shares are outstanding, with a floating share count of 96.92M. Insiders hold about 2.60% of the company’s shares, while institutions hold 92.54% stake in the company. Shares short for NBIX as of 1711584000 were 2426109 with a Short Ratio of 2.75, compared to 1709164800 on 2176456. Therefore, it implies a Short% of Shares Outstanding of 2426109 and a Short% of Float of 2.8299998.
Earnings Estimates
Currently, Neurocrine Biosciences, Inc. analysts are dedicated to thoroughly evaluating and rating the performance of Neurocrine Biosciences, Inc. (NBIX) in the stock market.The consensus estimate for the next quarter is $14.08, with high estimates of $0.10 and low estimates of $5.38.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
